Revision as of 13:43, 30 January 2023 edit Entranced98 (talk \| contribs) Extended confirmed users, Pending changes reviewers, Rollbackers 127,604 edits Importing Wikidata short description: "Combination drug" Tag: Shortdesc helper ← Previous edit		Revision as of 06:29, 24 May 2024 edit undo Whywhenwhohow (talk \| contribs) Autopatrolled, Extended confirmed users, Pending changes reviewers 44,561 edits update infobox, links, templates Next edit →
Line 1: {{Short description\|Combination drug}} ~~{{One source\|date=July 2020}}~~ {{Use American English\|date=July 2020}} {{Use dmy dates\|date=July 2020}} {{cs1 config \|name-list-style=vanc \|display-authors=6}} {{Infobox drug ~~\| drug_name =~~ \| type = combo \| image = Line 17 ⟶ 15: <!-- Combo data --> \| component1 = Arginine \| class1 = [[Amino acid]] \| component2 = Lysine \| class2 = [[Amino acid]] <!-- Clinical data --> \| pronounce = \| tradename = ~~LysaKare~~Lysakare \| Drugs.com = \| MedlinePlus = ~~\| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->~~ ~~\| licence_EU = yes~~ \| DailyMedID = ~~\| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->~~ \| pregnancy_AUえーゆー = <!-- A / B1 / B2 / B3 / C / D / X --> \| pregnancy_AUえーゆー_comment = ~~\| pregnancy_US = <!-- A / B / C / D / X / N -->~~ ~~\| pregnancy_US_comment =~~ \| pregnancy_category= \| routes_of_administration = [[Intravenous infusion]]▼ ~~\| dependency_liability =~~ ~~\| addiction_liability =~~ ▲\| routes_of_administration = Intravenous infusion ~~\| ATCvet =~~ \| ATC_prefix = V03 \| ATC_suffix = AF11 Line 54 ⟶ 44: \| legal_NZ = <!-- Class A, B, C --> \| legal_NZ_comment = \| legal_UK = POM ~~\| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->~~ \| legal_UK_comment = <ref>{{cite web \| title=Lysakare Summary of Product Characteristics (SmPC) \| website=(emc) \| date=2 May 2024 \| url=https://www.medicines.org.uk/emc/product/12724/smpc \| access-date=24 May 2024}}</ref> ~~\| legal_UK_comment =~~ \| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> \| legal_US_comment = \| legal_EU = Rx-only \| legal_EU_comment = <ref name="LysaKare EPAR" /> \| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> \| legal_UN_comment = Line 65 ⟶ 55: <!-- Identifiers --> ~~\| CAS_number_Ref =~~ \| CAS_number = 2447636-40-8 \| PubChem = \| IUPHAR_ligand = ~~\| DrugBank_Ref =~~ \| DrugBank = ~~\| ChemSpiderID_Ref =~~ \| ChemSpiderID = ~~\| UNII_Ref =~~ \| UNII = ~~\| KEGG_Ref =~~ \| KEGG = D12136 ~~\| ChEBI_Ref =~~ \| ChEBI = ~~\| ChEMBL_Ref =~~ \| ChEMBL = \| NIAID_ChemDB = Line 86 ⟶ 70: }} '''Arginine/lysine''', sold under the brand name '''~~LysaKare~~Lysakare''', is a fixed-dose [[combination medication]] used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called [[DOTA-TATE#Lutetium Lu 177\|lutetium (<sup>177</sup>Lu) oxodotreotide]].<ref name="LysaKare EPAR">{{cite web \| title=~~LysaKare~~Lysakare EPAR \| website=[[European Medicines Agency]] (EMA) \| date=24 May 2019 \| url=https://www.ema.europa.eu/en/medicines/human/EPAR/lysakare \| access-date=22 July 2020}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> It contains <small>L</small>-[[arginine]] hydrochloride and <small>L</small>-[[lysine]] hydrochloride.<ref name="LysaKare EPAR" /> The most common side effects include nausea and vomiting.<ref name="LysaKare EPAR" /> Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.<ref name="LysaKare EPAR" /> Side effects with arginine/lysine are usually mild or moderate.<ref name="LysaKare EPAR" /> Line 95 ⟶ 79: == Medical uses == Arginine/lysine is [[indicated]] for reduction of renal radiation exposure during [[peptide receptor radionuclide therapy]] (PRRT) with lutetium (<sup>177</sup>Lu) oxodotreotide in adults.<ref name="LysaKare EPAR" /> == References == {{Reflist}} {{Detoxifying agents for antineoplastic treatment}} ~~== External links ==~~ {{Portal bar \| Medicine}}▼ * {{cite web \| url = https://druginfo.nlm.nih.gov/drugportal/rn/74-79-3 \| publisher = U.S. National Library of Medicine \| work = Drug Information Portal \| title = Arginine }} {{Authority control}} * {{cite web \| url = https://druginfo.nlm.nih.gov/drugportal/name/lysine \| publisher = U.S. National Library of Medicine \| work = Drug Information Portal \| title = Lysine }} ▲{{Portal bar \| Medicine}} {{DEFAULTSORT:Arginine Lysine}}

Arginine/lysine: Difference between revisions